现在位置 >首页 > 时讯速递
0℃
Original Investigation May 11, 2020 Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State Eli S. Rosenberg, PElizabeth M. Dufort, Tomoko Udo, et al JAMA. Published online May 11, 2020. doi:10.1001/jama.2020.8630 Abstract Importance Hydroxychloroquine, with or without azithromycin, has been considered as a possible therapeutic agent for patients with coronavir...
阅读全文
0℃
ORIGINAL ARTICLE Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 Joshua Geleris, Yifei Sun, Jonathan Platt, et al N Engl J Med May 7, 2020DOI: 10.1056/NEJMoa2012410 Abstract BACKGROUND Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use. METHODS We examined the association between hydroxychloroquine use and intubation or death at a large medical center...
阅读全文
0℃
ARTICLES|ONLINE FIRST Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study Giulio Cavalli, Giacomo De Luca, Corrado Campochiaro, et al Lancet Rheumatol Published:May 07, 2020 DOI:https://doi.org/10.1016/S2665-9913(20)30127-2 Summary Background Mortality of patients with coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARD...
阅读全文
0℃
ARTICLES|ONLINE FIRST Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial Ivan Fan-Ngai Hung, Kwok-Cheung Lung, Eugene Yuk-Keung Tso, et al Lancet Published:May 08, 2020 DOI:https://doi.org/10.1016/S0140-6736(20)31042-4 Summary Background Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVI...
阅读全文
0℃
JAMA Insights Clinical UpdateMarch 11, 2020 Care for Critically Ill Patients With COVID-19 Srinivas Murthy, Charles D. Gomersall, Robert A. Fowler JAMA. 2020;323(15):1499-1500. doi:10.1001/jama.2020.3633 Initial reports suggest that COVID-19 is associated with severe disease that requires intensive care in approximately 5% of proven infections.1 Given how common the disease is becoming, as in prior major severe acute respiratory infection outbreaks—S...
阅读全文
0℃
Original Investigation April 22, 2020 Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area Safiya Richardson, Jamie S. Hirsch, Mangala Narasimhan, et al JAMA. Published online April 22, 2020. doi:10.1001/jama.2020.6775 Abstract Importance There is limited information describing the presenting characteristics and outcomes of US patients requiring hospitalization for...
阅读全文
0℃
May 6, 2020 Interpreting Diagnostic Tests for SARS-CoV-2 Nandini Sethuraman, Sundararaj Stanleyraj Jeremiah, Akihide Ryo JAMA. Published online May 6, 2020. doi:10.1001/jama.2020.8259 The pandemic of coronavirus disease 2019 (COVID-19) continues to affect much of the world. Knowledge of diagnostic tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still evolving, and a clear understanding of the nature of the tests and interpre...
阅读全文
0℃
ORIGINAL ARTICLE Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19 Harmony R. Reynolds, Samrachana Adhikari, Claudia Pulgarin, et al N Engl J Med May 1, 2020DOI: 10.1056/NEJMoa2008975 Abstract BACKGROUND There is concern about the potential of an increased risk related to medications that act on the renin–angiotensin–aldosterone system in patients exposed to coronavirus disease 2019 (Covid-19), because the viral receptor is angiot...
阅读全文
0℃
ORIGINAL ARTICLE Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19 Giuseppe Mancia, Federico Rea, Monica Ludergnani, et al N Engl J Med May 1, 2020DOI: 10.1056/NEJMoa2006923 Abstract BACKGROUND A potential association between the use of angiotensin-receptor blockers (ARBs) and angiotensin-converting–enzyme (ACE) inhibitors and the risk of coronavirus disease 2019 (Covid-19) has not been well studied. METHODS We carried out a po...
阅读全文
0℃
ORIGINAL ARTICLE Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 Mandeep R. Mehra, Sapan S. Desai, SreyRam Kuy, et al N Engl J Med May 1, 2020DOI: 10.1056/NEJMoa2007621 Abstract BACKGROUND Coronavirus disease 2019 (Covid-19) may disproportionately affect people with cardiovascular disease. Concern has been aroused regarding a potential harmful effect of angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs...
阅读全文
×
腾讯微博